Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric APL treatment study with arsenic trioxide and all-trans retinoic acid
2017-002383-40Phase 2Active
- Sponsor
- Italian Association of Pediatric Hematology and Oncology
- Start
- Oct 2018
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of arsenic trioxide, tretinoin and gemtuzumab ozogamicin in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Italian Association of Pediatric Hematology and Oncology. Primary endpoints: Event-free survival, 3-year event-free survival probability in standard-risk patients and 1 more. Started Oct 2018; status: active.
02
Drugs
arsenic trioxidetretinoingemtuzumab ozogamicin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on 2017-002383-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002383-40.